Savara (NASDAQ:SVRA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Savara (NASDAQ:SVRA) from a sell rating to a hold rating in a research report sent to investors on Saturday.

A number of other brokerages have also commented on SVRA. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a report on Wednesday, October 8th. Citizens Jmp decreased their target price on Savara from $11.00 to $10.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 13th. Lifesci Capital raised Savara to a “strong-buy” rating in a research report on Tuesday, October 14th. HC Wainwright lifted their price target on Savara from $5.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday, September 3rd. Finally, Oppenheimer boosted their price target on Savara from $8.00 to $9.00 and gave the company an “outperform” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $8.29.

Savara Trading Down 2.3%

Shares of Savara stock opened at $4.20 on Friday. The business has a fifty day simple moving average of $3.81 and a two-hundred day simple moving average of $3.07. Savara has a 1 year low of $1.89 and a 1 year high of $4.51. The company has a market capitalization of $854.57 million, a price-to-earnings ratio of -8.40 and a beta of 0.45. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Research analysts forecast that Savara will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of SVRA. Bank of New York Mellon Corp raised its stake in Savara by 3.7% in the first quarter. Bank of New York Mellon Corp now owns 262,935 shares of the company’s stock valued at $728,000 after purchasing an additional 9,305 shares in the last quarter. Y Intercept Hong Kong Ltd bought a new position in Savara in the 1st quarter valued at about $74,000. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Savara in the 1st quarter valued at approximately $381,000. Invesco Ltd. lifted its holdings in shares of Savara by 82.9% during the 1st quarter. Invesco Ltd. now owns 89,258 shares of the company’s stock worth $247,000 after acquiring an additional 40,461 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Savara during the 1st quarter worth approximately $1,067,000. Institutional investors own 87.93% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.